Downloads
Title
Source name
Date

The ILUMIEN IV Trial

The ILUMIEN IV Trial sciprian@crf.org Wed, 10/02/2024 - 12:09 Publish Date --> 2 hours 5 minutes ago Teaser --> Ziad Ali and C. Michael Gibson ta

TCTMD
02 Oct 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone? sciprian@crf.org Wed, 10/02/2024 - 09:50 Michael O'Riordan In one study, outcomes were similar regardless of

TCTMD
02 Oct 2024

TCTMD’s Top 10 Most Popular Stories for September 2024

TCTMD’s Top 10 Most Popular Stories for September 2024 sciprian@crf.org Tue, 10/01/2024 - 16:45 Shelley Wood Most of our top stories this month stemmed from the ESC Congress—

TCTMD
02 Oct 2024

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF sciprian@crf.org Tue, 10/01/2024 - 16:37 L.A. McKeown Among the trends in the report are a growing proportion of

TCTMD
02 Oct 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity sciprian@crf.org Tue, 10/01/2024 - 15:53 Todd Neale Indications that the GLP-1 drug has greater benefits

TCTMD
02 Oct 2024

Varipulse Pulsed-Field Ablation System Safe, Effective in Pivotal Trial

Varipulse Pulsed-Field Ablation System Safe, Effective in Pivotal Trial hdellabella@crf.org Mon, 09/30/2024 - 15:56 Todd Neale The system achieved safety and efficacy goals,

TCTMD
01 Oct 2024
We use cookies to enhance your browsing experience. By continuing to use our website you agree to our policies Read the policyAccept